| Aldosterone receptor antagonism and heart failure: insights from an outpatient clinic. | |
| | |
MedLine Citation:
|
PMID: 18613852 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: In randomized clinical trials, aldosterone antagonists have been shown to reduce mortality and morbidity in heart failure (HF). The aim of the present study was to examine the risk-benefit profile of aldosterone antagonists in routine clinical practice. METHODS: A retrospective analysis, extending over a 1-year period, of the clinical, instrumental and laboratory data of 264 HF outpatients was performed. All patients were on a beta-blocker and an ACE-inhibitor (or angiotensin-II receptor-blocker) and 151 were taking an aldosterone antagonist. RESULTS: At baseline, subjects treated with aldosterone antagonists had a higher NYHA class, a larger left-ventricular end-diastolic volume, a worse ejection fraction and a higher systolic pulmonary arterial pressure (sPAP). During follow-up, a greater reduction in sPAP and a tendency towards improved systolic and diastolic function were observed in subjects treated with aldosterone antagonists. Moreover, clinical and laboratory parameters did not deteriorate in patients taking aldosterone antagonists. Mortality rates were similar in the two groups (8.6% vs. 8.8%, P = NS). CONCLUSIONS: The use of aldosterone antagonists in HF is associated with an improvement in cardiac function and is well tolerated. In the present study, patients administered these agents had a comparable clinical outcome to that of the control group, despite important differences in baseline risk. |
| | |
Authors:
|
R Mariotti; G Borelli; M Coceani; S Zingaro; A Barison; I Morelli; L Rondinini |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Journal of clinical pharmacy and therapeutics Volume: 33 ISSN: 1365-2710 ISO Abbreviation: J Clin Pharm Ther Publication Date: 2008 Aug |
Date Detail:
|
Created Date: 2008-07-10 Completed Date: 2008-08-21 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8704308 Medline TA: J Clin Pharm Ther Country: England |
Other Details:
|
Languages: eng Pagination: 349-56 Citation Subset: IM |
Affiliation:
|
Heart Failure Unit, Department of Cardiothoracic, University of Pisa, Pisa, Italy. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adrenergic beta-Antagonists
/
therapeutic use Aged Aldosterone Antagonists / adverse effects, therapeutic use* Ambulatory Care Angiotensin II Type 1 Receptor Blockers / therapeutic use Angiotensin-Converting Enzyme Inhibitors / therapeutic use Blood Pressure / drug effects Drug Therapy, Combination Female Follow-Up Studies Heart Failure / drug therapy*, mortality Humans Male Middle Aged Randomized Controlled Trials as Topic Retrospective Studies Ventricular Function, Left / drug effects |
| Chemical | |
Reg. No./Substance:
|
0/Adrenergic beta-Antagonists; 0/Aldosterone Antagonists; 0/Angiotensin II Type 1 Receptor Blockers; 0/Angiotensin-Converting Enzyme Inhibitors |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Factors affecting the uptake of new medicines in secondary care - a literature review.
Next Document: Analysis using fluorescence polarization immunoassay for unbound teicoplanin concentration in serum.